

A FACTORIAL STUDY ON ENHANCEMENT OF SOLUBILITY AND DISSOLUTION RATE OF IBUPROFEN BY β CYCLODEXTRIN AND SOLUTOL HS15

KPR. Chowdary, Annamma Devi GS* and K. Susmitha

AU College of Pharmaceutical Sciences, Andhra University,
Visakhapatnam, Andhra Pradesh, India.

ABSTRACT

Ibuprofen, a widely prescribed anti-inflammatory drug belongs to class II under BCS and exhibit low and variable oral bioavailability due to its poor aqueous solubility. It is practically insoluble in water and aqueous fluids. As such its oral absorption is dissolution rate limited and it requires enhancement in the solubility and dissolution rate for increasing its oral bioavailability. The objective of the present study is to enhance the solubility and dissolution rate of ibuprofen by the use of β cyclodextrin (β CD) and Solutol HS15 (non ionic surfactant). The individual main effects and combined (or interaction) effect of β CD (Factor A) and Solutol HS15 (Factor B) in enhancing the solubility and dissolution rate of ibuprofen were evaluated in a 2^2 factorial study. The solubility of ibuprofen in water and water containing selected combinations of the two factors as per 2^2 factorial design was determined. The individual and combined effects of β CD and Solutol HS15 in enhancing the solubility of ibuprofen were highly significant ($P < 0.01$). β CD and Solutol HS15 alone gave respectively 12.83 and 42.32 fold increase in the solubility of ibuprofen. Combination of β CD with Solutol HS15 resulted in a much higher enhancement in the solubility of ibuprofen, 55.78 fold. The individual main and combined (interaction) effects of β CD (Factor A) and Solutol HS15 (Factor B) in enhancing the dissolution rate (K_1) and dissolution efficiency (DE_{30}) were highly significant ($P < 0.01$). β CD and Solutol HS15 alone gave respectively 7.78 and 19.41 fold increase in the dissolution rate of (K_1) of ibuprofen and in combination they gave a 27.11 fold increase in the dissolution rate (K_1) of ibuprofen. Combination of β CD with Solutol HS15 resulted in a much higher enhancement in the dissolution rate of ibuprofen than is possible with them alone. Solutol HS15 alone also gave higher enhancement in the dissolution rate (19.41 fold) and dissolution efficiency (3.23 fold) of ibuprofen. Hence a combination of β CD and Solutol HS15 or Solutol HS15 alone is recommended to enhance the solubility, dissolution rate and dissolution efficiency of ibuprofen, a poorly soluble BCS class II drug.

Keywords: Ibuprofen, Solubility, Dissolution Rate, β Cyclodextrin, Solutol HS15.

INTRODUCTION

Ibuprofen, a widely prescribed anti-inflammatory drug belongs to class II under BCS and exhibit low and variable oral bioavailability due to its poor aqueous solubility. It is practically insoluble in water and aqueous fluids. As such its oral absorption is dissolution rate limited and it requires enhancement in the solubility and dissolution rate for increasing its oral bioavailability. Several conventional methods such as micronization, chemical modification, use of surfactants and solubilizers, solid dispersion and a few new emerging technologies such as cyclodextrin complexation, mucoadhesive microspheres, nanoparticles, nanosuspensions, micro emulsion and self-emulsifying systems are available to enhance the solubility, dissolution rate and bioavailability of poorly soluble BCS Class II drugs¹. Among the various approaches complexation with cyclodextrins has gained good acceptance in recent years in industry for enhancing the solubility and dissolution rate of poorly soluble drugs. Cyclodextrins (CDs) are cyclic torus-shaped molecules with a hydrophilic outer surface and a lipophilic central cavity which can accommodate a variety of lipophilic drugs. As a consequence of inclusion process many physico-chemical properties such as solubility, dissolution rate, and bioavailability can be favourably affected^{2,3}. Cyclodextrins have been receiving increasing application in pharmaceutical formulation in recent years due to their approval by various regulatory agencies^{4,5}.

Surfactants increase the solubility of lipophilic water-insoluble drugs by micellar solubilization. Solutol HS15, a non ionic surfactant consists of polyglycol mono- and di-esters of 12-hydroxystearic acid with about 30% polyethylene glycol. Solutol HS15 has been shown to be safe in various animal toxicity models. Solutol HS15 has been approved in Canada and Argentina in marketed injectable drug products. Solutol HS15 has been used as an excellent solubilizer for liquid-filled capsules⁶. It is also reported as a carrier for solid dispersions of nifedipine for enhancing its dissolution rate⁷.

Though cyclodextrin complexation and use of Solutol HS15 for enhancing the solubility and dissolution rate of poorly soluble drugs have been investigated individually, no reports are available on their combined use in enhancing the solubility and dissolution rate of poorly soluble drugs. The objective of the present study is to enhance the solubility and dissolution rate

of ibuprofen by the use of β cyclodextrin (β CD) and Solutol HS15. The individual main effects and combined (or interaction) effect of β CD and Solutol HS15 in enhancing the solubility and dissolution rate of ibuprofen were evaluated in a 2² factorial study.

EXPERIMENTAL

Materials

Ibuprofen was a gift sample from M/s. Eisai Pharmatechnology and Manufacturing Pvt. Ltd., Visakhapatnam. β Cyclodextrin was gift sample from M/s. Cerestar Inc., USA. Methanol (Qualigens), Solutol HS15 were procured from commercial sources. All other materials used were of pharmacopoeial grade.

Methods

Estimation of Ibuprofen

An UV Spectrophotometric method based on the measurement of absorbance at 221 nm in phosphate buffer pH 7.2 was used for the estimation of ibuprofen. The method was validated for linearity, accuracy, precision and interference. The method obeyed Beer's law in the concentration range of 0-10 μ g/ml. When a standard drug solution was repeatedly assayed (n=6), the relative error and coefficient of variance were found to be 0.45% and 1.10 % respectively. No interference by the excipients used in the study was observed.

Solubility Determination

Excess drug (50 mg) was added to 15 ml of each fluid taken in a 25 ml stoppered conical flask and the mixtures were shaken for 24 h at room temperature (28 \pm 1 $^{\circ}$ C) on Rotary Flask Shaker. After 24 h of shaking, 2 ml aliquots were withdrawn at 2 h interval and filtered immediately using a 0.45 μ disk filter. The filtered samples were diluted suitably and assayed for ibuprofen by measuring absorbance at 221 nm. Shaking was continued until two consecutive estimations are the same. The solubility experiments were replicated for four times each (n=4).

Preparation of Ibuprofen - β CD Complexes

Solid inclusion complexes of ibuprofen - β CD - Solutol HS 15 were prepared as per 2² - factorial study by kneading method. Ibuprofen, β CD and Solutol HS 15 were triturated in a mortar with a small volume of solvent consisting of a blend of water: methanol (1:1). The thick slurry formed was kneaded for 45 min and then

dried at 55°C until dry. The dried mass was powdered and sieved to mesh No. 120.

Dissolution Rate Study

The dissolution rate of ibuprofen as such and from β CD complexes prepared was studied in 900 ml phosphate buffer pH 7.2 using Disso 2000 (Labindia) 8-station dissolution test apparatus with a paddle stirrer at 50 rpm. A temperature $37 \pm 1^\circ\text{C}$ was maintained throughout the study. Ibuprofen or ibuprofen - β CD complex equivalent to 50 mg of ibuprofen was used in each test. Samples of dissolution media (5 ml) were withdrawn through a filter (0.45 μ) at different intervals of time, suitable diluted and assayed for ibuprofen at 221 nm. The sample of dissolution fluid withdrawn at each time was replaced with fresh fluid. The dissolution experiments were replicated three times each (n=3).

Analysis of Data

Solubility and dissolution data were analyzed by Analysis of Variance (ANOVA) as per 2^2 factorial study.

RESULTS AND DISCUSSION

The individual main and combined (interaction) effects of β CD (Factor A) and Solutol HS15 (Factor B) on the aqueous solubility of ibuprofen were evaluated in a 2^2 -factorial experiment. For this purpose, two levels of β CD (0, 5 mM) and two levels of Solutol HS15 (0, 2%) were selected and the corresponding four treatments involved in the 2^2 -factorial study were purified water (1); water containing 5 mM β CD (a); water containing 2% Solutol HS15 (b) and water containing 5 mM β CD and 2% Solutol HS15 (ab).

The solubility of ibuprofen in the above mentioned fluids was determined (n=4) and the results are given in Table 1.

Table 1: Solubility of Ibuprofen in Various Fluids as per 2^2 - Factorial Study

| Fluids (Code as per 2^2 - Factorial Experiment) | Solubility (mg/100 ml) (n=4) (\bar{x})(s.d) | Increase in Solubility (Number of Folds) |
|---|---|--|
| Distilled water (1) | 12.42 \pm 0.32 | --- |
| Water containing 5 mM HP β CD (a) | 159.37 \pm 1.52 | 12.83 |
| Water containing 2% Solutol HS 15 (b) | 525.64 \pm 13.03 | 42.32 |
| Water containing 5 mM HP β CD and 2% Solutol HS 15 (ab) | 692.80 \pm 12.72 | 55.78 |

The solubility data were subjected to Analysis of Variance (ANOVA) to find out the significance of

main and combined effects of β CD and Solutol HS15 on the solubility of ibuprofen.

Table 2: ANOVA of Solubility Data

| Source of Variation | D F | S.S | MSS (SS/DF) | F - Ratio |
|---------------------|-----|------------|-------------|-----------|
| Total | 15 | 1195660.1 | 79710.68 | |
| Treatment | 3 | 1194658 | 398219.32 | 4768.22 |
| Error | 12 | 1002.18 | 83.52 | |
| Factor A | 1 | 98688.30 | 98688.30 | 1181.67 |
| Factor B | 1 | 1095562.72 | 1095562.72 | 13118.11 |
| Factor AB | 1 | 406.93 | 406.93 | 4.87 |

$$F_{0.05}(3, 12) = 3.49; F_{0.05}(1, 12) = 4.75; F_{0.01}(3, 12) = 5.95; F_{0.01}(1, 12) = 9.33$$

The results of ANOVA (Table 2) indicated that the individual effects of β CD and Solutol HS15 in enhancing the solubility of ibuprofen were highly significant ($P < 0.01$). The combined effects of β CD and Solutol HS15 were also found to be significant ($P < 0.05$). β CD and Solutol HS15 alone gave a 12.83 and 42.32 fold increase in the solubility of ibuprofen respectively. Whereas the combination of β CD with Solutol HS15

resulted in a much higher enhancement in the solubility of ibuprofen, 55.78 fold.

To evaluate the individual and combined effects of β CD and Solutol HS15 on the dissolution rate of ibuprofen, solid inclusion complexes of ibuprofen- β CD were prepared with and without Solutol HS15 as per 2^2 -factorial design. For this purpose two levels of β CD (0 and 1:2 ratio of drug : β CD) and two levels of Solutol HS15 (0

and 2%) were selected and the corresponding four treatments involved in the 2^2 -factorial study were ibuprofen pure drug (1); ibuprofen- β CD (1:2) inclusion complex (a); ibuprofen - Solutol HS15 (2%) binary complex (b) and ibuprofen- β CD (1:2) - Solutol HS15 (2%) inclusion complex (ab).

The CD complexes were prepared by kneading method. All the solid inclusion complexes of

ibuprofen- β CD - Solutol HS15 prepared were found to be fine and free flowing powders. Low coefficient of variation (c.v.) values ($< 1.1\%$) in the percent drug content indicated uniformity of drug content in each batch of solid inclusion complexes prepared. The dissolution rate of ibuprofen alone and from β CD complexes was studied in phosphate buffer of pH 7.2. The dissolution profiles are given in Fig 1.




Fig. 1: Dissolution Profiles of Ibuprofen- β CD- Solutol HS15 Inclusion Complexes Prepared as per 2^2 Factorial Design

The dissolution of ibuprofen followed first order kinetics with r (correlation coefficient) above 0.9053. Dissolution efficiency (DE_{30}) values were calculated as suggested by Khan⁸. The dissolution parameters are given in Table 3. The

dissolution of ibuprofen was rapid and higher in the case of ibuprofen- β CD - Solutol HS15 complex systems prepared when compared to ibuprofen pure drug as such.

Table 3: Dissolution Parameters of Ibuprofen - β CD- Solutol HS15 Inclusion Complexes

| Formulation Code as per 2^2 Factorial Study | PD ₁₀ (%) | | DE ₃₀ (%) | | K ₁ x 10 ² (min ⁻¹) | |
|---|----------------------|---|----------------------|---|---|---|
| | $\bar{X} \pm s.d$ | Increase in PD ₁₀ (no. of folds) | $\bar{X} \pm s.d$ | Increase in DE ₃₀ (no. of folds) | $\bar{X} \pm s.d$ | Increase in K ₁ (no. of folds) |
| 1 | 26.21±3.05 | -- | 26.21±1.51 | - | 1.01±0.30 | - |
| A | 55.27±3.37 | 2.10 | 63.21±1.94 | 2.41 | 7.86±0.51 | 7.78 |
| B | 85.74±4.77 | 3.27 | 84.88±0.56 | 3.23 | 19.61±1.41 | 19.41 |
| Ab | 93.49±0.80 | 3.56 | 88.36±0.57 | 3.37 | 27.38±1.22 | 27.11 |

Table 4: ANOVA of Dissolution Rate (K_1) Data

| Source of Variation | D F | S.S | MSS (SS/DF) | F - Ratio |
|---------------------|-----|---------|-------------|-----------|
| Total | 11 | 1258.61 | 114.41 | |
| Treatment | 3 | 1250.87 | 416.95 | 430.97 |
| Error | 8 | 7.73 | 0.96 | |
| Factor A | 1 | 160.29 | 160.29 | 165.67 |
| Factor B | 1 | 1089.99 | 1089.98 | 1126.61 |
| Factor AB | 1 | 0.61 | 0.61 | 0.63 |

$F_{0.05}(3, 8) = 4.07$; $F_{0.05}(1, 8) = 5.32$; $F_{0.01}(3, 8) = 7.59$; $F_{0.01}(1, 8) = 11.3$

Table 5: ANOVA of Dissolution Efficiency (DE_{30}) Data

| Source of Variation | D F | S.S | MSS (SS/DF) | F - Ratio |
|---------------------|-----|---------|-------------|-----------|
| Total | 11 | 7355.58 | 668.68 | |
| Treatment | 3 | 7342.12 | 2447.37 | 1454.21 |
| Error | 8 | 13.46 | 1.68 | |
| Factor A | 1 | 1228.87 | 1228.86 | 730.18 |
| Factor B | 1 | 5270.77 | 5270.77 | 3131.87 |
| Factor AB | 1 | 842.48 | 842.48 | 500.59 |

$F_{0.05}(3, 8) = 4.07$; $F_{0.05}(1, 8) = 5.32$; $F_{0.01}(3, 8) = 7.59$; $F_{0.01}(1, 8) = 11.3$

The dissolution rate (K_1) and dissolution efficiency (DE_{30}) values were subjected to ANOVA to find out the significance of the main and combined effects of β CD and Solutol HS15 on the dissolution rate and dissolution efficiency of ibuprofen. The results of ANOVA (Tables 4 - 5) indicated that the individual main effects of β CD (Factor A) and Solutol HS15 (Factor B) in enhancing the dissolution rate (K_1) and dissolution efficiency (DE_{30}) were highly significant ($P < 0.01$).

β CD and Solutol HS15 alone gave respectively 7.78 and 19.41 fold increase in the dissolution rate of (K_1) of ibuprofen and in combination they gave a 27.11 fold increase in the dissolution rate (K_1) of ibuprofen. Thus, combination of β CD with Solutol HS15 resulted in a much higher enhancement in the dissolution rate of ibuprofen than is possible with them alone. Combination of β CD with Solutol HS15 also gave higher enhancement in the dissolution efficiency (DE_{30}) of ibuprofen.

CONCLUSIONS

1. The individual and combined effects of β CD and Solutol HS15 in enhancing the solubility of ibuprofen were highly significant ($P < 0.01$).

2. β CD and Solutol HS15 alone gave respectively 12.83 and 42.32 fold increase in the solubility of ibuprofen. Combination of β CD with Solutol HS15 resulted in a much higher enhancement in the solubility of ibuprofen, 55.78 fold.
3. The individual main and combined (interaction) effects of β CD (Factor A) and Solutol HS15 (Factor B) in enhancing the dissolution rate (K_1) and dissolution efficiency (DE_{30}) were highly significant ($P < 0.01$).
4. β CD and Solutol HS15 alone gave respectively 7.78 and 19.41 fold increase in the dissolution rate of (K_1) of ibuprofen and in combination they gave a 27.11 fold increase in the dissolution rate (K_1) of ibuprofen.
5. Combination of β CD with Solutol HS15 resulted in a much higher enhancement in the dissolution rate of ibuprofen than is possible with them alone.
6. Solutol HS15 alone also gave higher enhancement in the dissolution rate (19.41 fold) and dissolution efficiency (3.23 fold) of ibuprofen.

7. Hence a combination of β CD and Solutol HS15 or Solutol HS15 alone is recommended to enhance the solubility, dissolution rate and dissolution efficiency of ibuprofen, a poorly soluble BCS class II drug.

REFERENCES

1. Chowdary, K.P.R. and Madhavi, B.L.R., Indian Drugs, 42(9): 557-562, 2005.
2. Fromming, K.H. and Szejtli, J., Cyclodextrins in Pharmacy, Kluwer Academic Publications, Dordrecghi, p. 20, 1994.
3. Duchene, D. and Woussidjewe, D., in ed.: S. Dumitriu, Polysaccharides in Medical Applications, Marcel Dekker, New York, p. 575, 1996.
4. Thompson, D.O., Crit. Rev. Ther. Drug Carrier Syst., 14 (1), 1997.
5. Hedges, A.R., Chem. Rev., 98, 2035, 1998.
6. Rajebahadur, M., Zia, H., Nues, A. and Lee, C., Drug Delivery, 13(3), 201-6, 2006.
7. Sherry, Ku. and Ranga, Velagaleti, Pharmaceutical Technology, Nov. 2, 108-110, 2010.
8. Khan, K.A., Journal of Pharmacy and Pharmacology, 27, 48-49, 1975.